Last reviewed · How we verify
L-carnitine
L-carnitine, marketed by Asan Medical Center, is positioned in the niche market for mobilizing fat deposits and cellulite. A key strength is the protection of its core composition through a patent expiring in 2028, providing a barrier to generic competition. The primary risk lies in the lack of reported revenue and key trial results, which may limit investor confidence and market expansion.
At a glance
| Generic name | L-carnitine |
|---|---|
| Also known as | motova plus, Sigma-Tau, levocarnitine, L-Carnitine, Levocarnitine, carnitine, Carnitor® |
| Sponsor | Asan Medical Center |
| Drug class | Carnitine Analog [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Mobilization of fat deposits and cellulite
Common side effects
Key clinical trials
- Effects of Carnitine Supplementation on Exercise-Induced Muscle Damage: A Randomized Controlled Trial (NA)
- Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. (PHASE3)
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment (NA)
- Impact of CRRT on Serum Carnitine and Micronutrient Levels
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma (PHASE3)
- Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program
- Effect of L-Carnitine Supplementation in Preterm Neonates (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-carnitine CI brief — competitive landscape report
- L-carnitine updates RSS · CI watch RSS
- Asan Medical Center portfolio CI